Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | COMT | P21964 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068594 | 0.88 | TAAR1 (0.47) | SCN4ALMNAUSP2HRH2TAAR1 | |
| SCHEMBL1570369 | 0.77 | USP2 (0.53) | LMNAUSP2HRH2NPC1RAB9A | |
| SCHEMBL27953115 | 0.73 | SCN4A (0.51) | SCN4ACOMTLMNANPC1RAB9A | |
| SCHEMBL269952 | 0.72 | CALM1 (0.65) | LMNATAAR1ALDH1A1LTA4HTSHR | |
| SCHEMBL1149871 | 0.71 | USP2 (0.55) | SCN4ACOMTLMNAUSP2HRH2 | |
| SCHEMBL1570877 | 0.70 | POLB (0.57) | ALDH1A1KDM4ESMN1; SMN2KCNH2TSHR | |
| SCHEMBL27326 | 0.70 | CALM1 (0.71) | LMNATAAR1ALDH1A1LTA4HTSHR | |
| SCHEMBL27647887 | 0.69 | TAAR1 (0.43) | COMTLMNATAAR1HRH3TSHR | |
| Methane SCHEMBL9562367 | 0.68 | CALM1 (0.67) | LMNATAAR1ALDH1A1LTA4HTSHR | |
| SCHEMBL27942544 | 0.68 | NTRK1 (0.49) | LMNAUSP2HRH2KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020988-A3 | METHOD AND APPARATUS TO ENABLE SWITCHING BETWEEN TWO CARRIERS IN A CELLULAR COMMUNICATION NETWORK | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-05-10 | — | — | WO | disclosed |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7867991-B2 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1886683-B1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | BETHESDA PHARMACEUTICALS INC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7812046-B2 | PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1886683-A1 | Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1878427-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20080009536-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1839660-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | Bethesda Pharmaceuticals, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070203213-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070185070-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7232828-B2 | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1536785-B1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1536785-A4 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1536785-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | Bethesda Pharmaceuticals, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004014308-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242712-A1 | Identification and uses of novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | SCN4A 2937/4885COMT 4121/4885LMNA 1993/4885 |
| US-20080009536-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | SCN4A 2896/4885COMT 3904/4885LMNA 2046/4885 |
| US-20110046188-A1 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS | HDLBP, PPARA, PPARG | SCN4A 3196/4885COMT 2268/4885LMNA 1444/4885 |
| US-20070185070-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | SCN4A 2896/4885COMT 3904/4885LMNA 2046/4885 |
| US-20120094913-A1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | PPARA, PPARG, PPARD | SCN4A 2896/4885COMT 3904/4885LMNA 2046/4885 |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | SCN4A 2896/4885COMT 3904/4885LMNA 2046/4885 |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | HDLBP, PPARA, PPARG | SCN4A 3196/4885COMT 2268/4885LMNA 1444/4885 |
| US-20070203213-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | SCN4A 2896/4885COMT 3904/4885LMNA 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.